DS probiotics have an inhibitory effect on Helicobacter pylori, reducing its colonization and activity in the stomach. Additionally, a large population of active probiotics can interfere with or prevent the attachment of Helicobacter pylori to the gastric mucosa, thereby reducing the risk of infection.

In addition to its anti-infective effects, probiotics can also regulate the body’s immune function, improve the gastrointestinal microecological environment and enhance patient compliance with Helicobacter pylori eradication therapy.

The microecological immunotherapy of probiotics relies on the principle of “bacteria inhibiting bacteria,” which maximizes the competitive interaction between microorganisms, yielding rapid and long-lasting effects. It helps establish a healthy balance of intestinal microflora, inhibiting the growth of harmful bacteria and maintaining overall health.

• Common symptoms of Helicobacter pylori infection include acid reflux, heartburn, stomach pain and bad breath. These symptoms are often caused by the excessive secretion of gastrin induced by Helicobacter pylori. For patients with gastric ulcers, Helicobacter pylori infection may lead to severe stomach pain and is considered a major cause of bad breath.

   

• Helicobacter pylori infection can also cause chronic gastritis, with main clinical manifestations including discomfort and dull pain in the upper abdomen, sometimes accompanied by belching, acid reflux, nausea and vomiting. This infection progresses slowly and tends to recur.

   

• Helicobacter pylori infection can lead to the production of various pathogenic factors, resulting in damage to the gastric mucosa. Patients infected with Helicobacter pylori often experience acid reflux, belching and bloating, with a significantly higher incidence compared to those not infected with this bacterium.

The difficulty in treating Helicobacter pylori lies primarily in its complex pathogenic mechanisms. The bacterium secretes urease which breaks down urea into ammonia, forming a protective zone in the stomach that allows H. pylori to survive in acidic environments. To neutralize this acidic environment, the body produces more gastric acid, further lowering the pH of the stomach and causing damage to gastric cells.

Moreover, during H. pylori infection, the bacterium secretes toxic substances such as neutrophil-activating protein and VacA cytotoxin, which continuously damage cells. Consequently, cell damage combined with the exacerbation of acidic conditions increases the risk of patients developing gastric ulcers, gastritis or even gastric cancer.